February 13, 2019 – Mayne Pharma has announced the launch of Lexette™ (halobetasol) foam 0.05%. The product is a new formulation of halobetasol, a high strength corticosteroid used to treat plaque psoriasis.
Lexette is approved for use in patients who are at least 18 years of age as a topical treatment. Recommended dosing is a thin layer applied to affected areas twice daily for up to two weeks. It should be rubbed in gently, and patients should not use more than 50g per week. The product will be available in 50g canisters.
With Lexette’s May 2018 FDA approval, Mayne Pharma was granted three years of marketing exclusivity. The product’s is available at an average wholesale price (AWP) of $924.86 for a 50g canister.